Skip to main content
Premium Trial:

Request an Annual Quote

Broad, Verily Extend Terra Bioinformatics Platform to Microsoft Azure

NEW YORK – The Broad Institute, Verily Life Sciences, and Microsoft on Monday announced a strategic partnership to extend the Terra bioinformatics analysis platform to the Microsoft Azure cloud.

The cloud-based Terra platform was codeveloped by the Broad and Google sibling Verily Life Sciences. By offering it on Azure, the three companies hope that they can improve collaboration among many of the 168,000 data scientists, biomedical researchers, and clinicians who use Terra.

"This partnership combines multimodal data, secure analytics, and scalable cloud computing to improve insight and evidence generation, allowing us to ultimately impact more patients' lives," Verily COO Stephen Gillett said in a statement.

"Both Microsoft and Verily share our vision for Terra as an open and collaborative ecosystem for the sharing and analysis of biomedical data," added the Broad's Clare Bernard, who manages the Terra platform. "This partnership will allow us to make Terra even more useful and accessible across a broader set of researchers and industries."

Gregory Moore, corporate VP of Microsoft Health Next, said that this arrangement will allow the tech giant to bring the security, privacy, scalability, and analytics capabilities of Azure to bioinformatics researchers worldwide.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.